Jump to content

Recommended Posts

Paul Edwards

Cabazitaxel is a chemotherapy treatment which is used when patients become resistant to chemotherapy treatment with Docetaxel.   Cabazitaxel improves overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with Docetaxel.

 

Androgen receptor splice variant 7 (AR-V7) in circulating tumuor cells (CTCs) from mCRPC patients was recently demonstrated to be associated with resistance to Abiraterone and Enzalutamide.

 

A group of Dutch and Belgian researchers investigated whether this was also true for Cabazitaxel.    They found that Cabazitaxel was effective even if AR-V7 was present.

 

Reference

"Efficacy of Cabazitaxel in Castration-resistant prostate cancer is independent of the presence of AR-V7 in Circulating Tumor Cells"   Wendy Ostenk et al
Article Information    DOI: 10.1016/j.eururo.2015.07.007

 

 

 

 

 

Link to post
Share on other sites
×
×
  • Create New...